Global Sleeping Bruxism Treatment Market Research Report: Information by Type (Primary Bruxism and Secondary Bruxism), Diagnosis (Clinical Examination, X-rays, Electromyographic Methods and Polysomnography), Treatment Type [Dental Approaches (Mouth Guard and NTI-TSS Device) and Medication (Muscle Relaxants, Botox Injections and Anti-anxiety Drugs)], Cause [Obstructive Sleep Apnea, Gastroesophageal Reflux Disease (GERD), Malocclusion and Sleep Paralysis], Patient Type [Pediatric and Adult (Male and Female)] - Forecast till 2027
ID: MRFR/Pharma/3979-CR | August 2019 | Region: Global | 151 pages
Market Scenario
Global Sleeping Bruxism Treatment Market is expected to register 6.7% CAGR and is projected to reach USD 638.2 million by 2023. Sleeping bruxism (SB), also called nocturnal tooth grinding, is a medical condition characterized by clenching or grinding of teeth during sleep. This is the sleep-associated movement disorder characterized by involuntary, unconscious movement during sleep. The use of psychoactive substances such as tobacco, alcohol, antidepressants, cigarette smoking, or caffeine increases sleep disorders and causes daytime sleepiness. Sleep bruxism is highly prevalent in people who consume psychoactive substances.
According to the Medical Expenditure Panel Survey (MEPS) 2013, one in six Americans consume antidepressants or a sedative. The United Nations reported in 2007 that approximately 1 billion people worldwide suffer from neurological disorders such as Alzheimer, Parkinson disease, strokes, multiple sclerosis, epilepsy, and others.
Factors representing the market growth are worldwide increasing the prevalence of sleep bruxism, growing child population, rising prevalence of obstructive sleep apnea, and changing lifestyle across the world. An article published in the Springer Nature journal stated that the prevalence of sleep bruxism is generally considered to be around 8 to 13% of the general population across the globe. On the contrary, the limited availability of treatment options and the high cost of custom-fit night guards are the factors anticipated to restrain the market growth during the forecast period.
Market Dynamics
The globally rising prevalence of obstructive sleep apnea (OSA) or obstructive sleep apnea-hypopnea is likely to propel the demand for sleeping bruxism diagnosis and treatment drugs. According to an article published in Lancet Respiratory Medicine (LRM), currently, the global prevalence of obstructive sleep apnea is estimated to be around 1 billion individuals. Another 425 million adults are expected to have moderate to severe obstructive sleep apnea across the world.
Global Sleeping Bruxism Treatment Market Size, by Region, 2017 (%)
Source: MRFR Analysis
Segmentation
Global sleeping bruxism treatment market has been segmented into type, diagnosis, treatment type, cause, patient type, and end-user.
Based on type, the global market has been divided into primary bruxism and secondary bruxism. Secondary bruxism occurs in the presence of few neurological disorders, medical or psychiatric conditions, or due to the side effects of drugs.
Based on diagnosis, the global market has been segmented into clinical examination, X-rays, electromyographic methods, and polysomnography.
By treatment type, the global market has been bifurcated into dental approaches and medication. The dental approaches segment is further classified into mouth guard and NTI-TSS device. The medication segment has been further categorized into muscle relaxants, Botox injections, and anti-anxiety drugs.
Based on cause, the global market has been segmented into obstructive sleep apnea, gastroesophageal reflux disease (GERD), malocclusion, and sleep paralysis.
By patient type, the global market has been divided into pediatric and adult. The adult segment has been further categorized into male and female.
Based on end-user, the global market has been divided into hospitals and dental clinics.
Regional Analysis
Based on region, the global sleeping bruxism treatment market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Rising prevalence of stress and anxiety, chronic sleep disorders and intermittent sleep problems, changing lifestyle, and the presence of prominent market players in the US and Canada are expected to support the dominance of the Americas during 2018 to 2023. For instance, according to the National Sleep Foundation, presently, 50 to 70 million Americans are affected by chronic sleep disorders and intermittent sleep problems, which significantly diminish health, attentiveness, and safety.
Europe follows the Americas in terms of revenue and is expected to register the fastest market growth over the forecast period. According to the European Orthodontic Society in 2018, sleeping bruxism affected 14% to 20% of children, 8% to 12% of teenagers, and 3% of the old population.
Asia-Pacific would register considerable market growth during the forecast period attributed to the rapid adoption of advanced healthcare technology, fast economic growth, large population size, and rising healthcare investments. As per the data presented by United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the percentage of the population aged 0 to14 was 23.5% in 2018, which is projected to decrease to 17.7% by 2050.
The Middle East & Africa is expected to represent least market growth owing to the less exposure to the healthcare services, lack of awareness about sleeping bruxism, ignorance of dental diseases, and lack of government rules and regulations.
Key Players
The prominent players in the global sleeping bruxism treatment market are Ivoclar Vivadent AG, Ipsen Biopharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Akervall Technologies Inc., PLANMECA OY, Randmark Dental Products, LLC, S4S Dental Laboratory, Patterson Dental Supply, Inc., Henry Schein, Inc., and Pfizer Inc.
These companies have adopted several organic and inorganic growth strategies to gain robust competitive advantages, such as mergers & acquisitions, new product launches, partnerships and collaborations, and joint ventures.
Key Updates
- In January 2019, Akervall Technologies Inc. launched a smart mouthguard, SISU mouthguards in the US. With this launch, the company extended its product portfolio
- In April 2018, Royal DSM, a Dutch multinational science-based company dealing in health, nutrition, and materials, partnered with 3Dmouthguard, a Netherlands-based company that digitalizes the complete process of custom made mouthguards, to develop custom-made and instantly printed 3D mouthguards to protect teeth and mouth injuries. This partnership strengthened the company’s position in the competitive market.
Market Segmentation
Global Sleeping Bruxism Treatment Market, by Type
- Primary Bruxism
- Secondary Bruxism
Global Sleeping Bruxism Treatment Market, by Diagnosis
- Clinical Examination
- X-Rays
- Electromyographic Methods
- Polysomnography
Global Sleeping Bruxism Treatment Market, by Treatment Type
- Dental Approaches
- Mouth Guard
- NTI-TSS Device
- Medication
- Muscle Relaxants
- Botox Injections
- Anti-anxiety Drugs
Global Sleeping Bruxism Treatment Market, by Patient Type
- Pediatric
- Adult
- Male
- Female
Global Sleeping Bruxism Treatment Market, by End User
- Hospitals
- Dental Clinics
Global Sleeping Bruxism Treatment Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- France
- UK
- Scandinavia
- Denmark
- Norway
- Sweden
- Finland
- Iceland
- Benelux Union
- Belgium
- Netherlands
- Luxembourg
- Italy
- Spain
- Switzerland
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
- Additional Companies
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Sanofi
- Johnson & Johnson Services, Inc.
- Mega Trends in the Market
- Pricing Analysis
Intended Audience
- Pharmaceutical manufacturers and distributors
- Medical device manufacturers and distributors
- Research and development (R&D) companies
- Market research and consulting service providers
- Potential investors
- Government research institutes
- Academic institutes and universities
Frequently Asked Questions (FAQ) :
Sleeping bruxism treatment market projected to grow at approximately 6.7% CAGR during the assessment period (2020-2027).
The valuation of the global sleeping bruxism treatment market is estimated to increase to USD 638.2 MN by the end of 2023.
Increasing prevalence of the disorder and growing funding & healthcare insurance coverage, are major tailwinds pushing the growth of the global sleeping bruxism treatment market.
North America holds the largest share in the global sleeping bruxism treatment market, followed by Europe and the Asia Pacific, respectively.
Ipsen Biopharmaceuticals, Inc., Pfizer Inc., Ivoclar Vivadent AG, Henry Schein, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Patterson Dental Supply, Inc., S4S Dental Laboratory, Akervall Technologies Inc., PLANMECA OY, and Randmark Dental Products, LLC, are some of the top players operating in the global sleeping bruxism treatment market.
Sleeping Bruxism Treatment – Summary
The global sleeping bruxism treatment market is expected to touch USD 638.22 million valuation by 2023, expanding at a modest CAGR of 6.7% during the forecast period (2018-2023), reports Market Research Future (MRFR). Sleeping bruxism is a disorder in which people grind or clench their teeth during sleep. This incident is quite natural. However, if the rate goes higher, it can damage the teeth or affect the jaw muscles.
According to a study published by Sleep Research Society (SRS), generally 5-8% people suffer from this disorder resulting in tooth wear and headaches which inadvertently distresses their lifestyle. This can give rise to preventive measures such as anti-depressants, mouth guard, muscle relaxants, and others and provide a favorable condition for the market.
Mayo Foundation’s report for the Medical Education and Research on sleeping bruxism reveals that the prevalence of bruxism among children varied from 3.5-40.6% and was seconded by the Journal of Conservative Dentistry. Both the reports suggested a hike in the number of affected children population. With the U.S. Census Bureau’s count of 74.7 million children by 2023, it has become even more disconcerting. This daunting number can drive the market further.
However, there is no specific cure for sleeping bruxism. The available medications have side-effects which destabilize the physiological system. This could impede the market growth during the forecast period.
Segmentation:
The global market for sleeping bruxism treatment can be segmented by type, diagnosis, treatment, cause, patient, and end-user.
By type, the market includes primary bruxism and secondary bruxism. Primary bruxism occurs without any medical condition, and mainly the clenching or grinding of teeth takes place. Currently, the predicted segment valuation is USD 168.74 million which it can achieve by 2023. Secondary bruxism is often triggered by neurological disorders or by psychoactive substance consumption. This segment accounted for 72.7 % of the global market share.
Diagnosis-wise segmentation includes clinical examination, electromyographic methods, polysomnography, x-ray, and others. The disorder is not life-threatening but can result in dental problems making its early diagnosis necessary.
Treatment-based segmentation includes dental approaches and medications. It’s not always necessary for children as they tend to outgrow it with age. However, severe cases demand treatment and the dental approaches segment could reach up to a significant valuation during the forecast period. Dental medication commanded around 68.6% of the global market in 2017.
Based on cause, the market comprises obstructive sleep apnea, sleep paralysis, gastroesophageal reflux disease (GERD), malocclusion, and others. Reports of National Sleep Foundation reveals that one in four people suffer from obstructive sleep apnea which gives rise to sleeping bruxism. The market for obstructive sleep apnea is projected to reach USD 233.20 million at a 7% CAGR during the review period.
Based on patient type, the market is segmented into pediatric and adult. According to KidsHealth, 3 out of 10 children suffer from bruxism. Pediatric segment currently dominates the market with 68.5% of the global share in 2017 and in the foreseeable future, is expected to do so by reaching USD 440.28 million mark with a CAGR of 6.8% during the prognosis period.
The end-user segment includes hospitals, dental clinics, and others. With considerable technological advancements, hospitals and clinics now have ample provisions to take care of the situation. As the frontrunner, hospitals and clinics are projected to reach USD 270.50 million valuation during the review period.
Regional Segmentation:
Geographically the market covers the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas dominated the market in 2017 by holding 39.1% of the market share. This is due to the rising cases of stress and anxiety related diseases among the populace. According to the American Sleep Association, 10% of the adults and 15% of the children are affected by the disease. Almost 8.3 million of the U.S. population are suffering from the disease as reported by the World Socialist Website in 2017. The market in the region, with an astounding 6.9% CAGR can reach USD 252.27 million by 2023.
Europe is the second largest market where as per the European Orthodontic Society in 2014-2015 sleeping bruxism was prevalent in 14 to 20% of children, 8 to 12% of teenagers and 3% of the adult population. Obstructive sleep apnea syndrome is also a significant factor in the growth of this market as according to the reports of the European Lung Foundation, 3-7% male and 2-5% female suffer from the disease.
APAC is expected to open up possibilities owing to its significant investment in healthcare, economic growth, large population base, and adoption of advanced healthcare technology. As per the reports of State of the World’s Children 2016, UNICEF, South Asia has 627 million children population, almost 36% of the total population and the number is on the rise giving the market a favorable condition. Also, bruxism and dental care related awareness are spreading rapidly in countries such as India, China, Japan and South Korea which can boost the market.
Market Competition:
APAC market is growing bigger day by day. According to the World Dental Show in 2017, the Indian dental market is expected to witness a staggering CAGR of 16% by the end of 2018 and reach USD 242.81 million valuation. In Australia, as per the reports of Snore Australia, 9% of women and 25% of men suffer from obstructive sleep apnea. This could also open up the market for further possibilities and also could lure in international players.
The key players operating in the market are Randmark Dental Products, LLC, S4S Dental Laboratory, Ipsen Biopharmaceuticals, Inc., Pfizer Inc. Henry Schein, Inc., PLANMECA OY, Patterson Dental Supply, Inc., Merz Pharma GmbH & Co. KGaA, Ivoclar Vivadent AG, Carestream Dental, Akervall Technologies Inc., and others.
Global Sleeping Bruxism Market: Competitive Landscape
The global sleeping bruxism treatment market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.
The growth of the market vendors is dependent on the market conditions, government support, and industry development. Thus, the vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although the international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time to new products and increase the global market share.
The vendors with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
Ipsen Biopharmaceuticals, Inc has a vast product portfolio in the sleeping bruxism treatment industry. The company also has a wide geographic presence as it operates in various countries across the world. They have a significant presence in North America, Europe, the Middle East & Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.
The top three manufacturers in the market are inclusive of:
- Randmark Dental Products, LLC
- S4S Dental Laboratory
- Ipsen Biopharmaceuticals, Inc.
Randmark Dental Products, LLC has 70 years of experience in clinical dentistry and occlusal therapy. The company's line of business includes the manufacturing of dental night guards. The company’s NiteBite is patented and is an FDA-cleared device that functions within the patient's freeway space. The strengths of the company are inclusive of patented & FDA cleared devices and skilled workforce. The company is focused on product enhancements to enhance its customer base in the United States.
S4S Dental Laboratory provides dental solutions such as occlusal splints that aids in the treatment of bruxism (facial pain, migraines, clenching, tooth wear, and TMJ dysfunction) and anti-snoring and sleep apnoea devices. The company complies with the requirements of DAMAS (Dental Appliance Manufacturers Audit Scheme) to enhance its quality management system. The company is focused on developing a wide range of products for dental and sleep-related breathing disorders. Moreover, the company’s focus is on building partnerships to provide holistic solutions.
Ipsen Biopharmaceuticals, Inc. provides treatment for oncology, neuroscience, and rare diseases. It has two operating segments, namely, specialty care and consumer healthcare. The company focuses on developing innovative solutions to fulfill the customers’ needs. Innovative drugs and skilled workforce followed by a Strong R&D are the major factors strengthening the presence of the company in the market.